247 related articles for article (PubMed ID: 36334180)
1. The exploitation of enzyme-based cancer immunotherapy.
Chandan G; Saini AK; Kumari R; Chakrabarti S; Mittal A; Sharma AK; Saini RV
Hum Cell; 2023 Jan; 36(1):98-120. PubMed ID: 36334180
[TBL] [Abstract][Full Text] [Related]
2. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.
Joshi S; Sharabi A
Pharmacol Ther; 2022 Jul; 235():108114. PubMed ID: 35122833
[TBL] [Abstract][Full Text] [Related]
3. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond.
Zhao Y; Du J; Shen X
Front Immunol; 2023; 14():1157537. PubMed ID: 37006306
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of targeting MDSCs in tumor microenvironment.
Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y
Front Immunol; 2022; 13():990463. PubMed ID: 36131911
[TBL] [Abstract][Full Text] [Related]
5. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
[TBL] [Abstract][Full Text] [Related]
6. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.
Davis RJ; Van Waes C; Allen CT
Oral Oncol; 2016 Jul; 58():59-70. PubMed ID: 27215705
[TBL] [Abstract][Full Text] [Related]
7. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.
Nakamura K; Smyth MJ
Cell Mol Immunol; 2020 Jan; 17(1):1-12. PubMed ID: 31611651
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.
Wu Y; Yi M; Niu M; Mei Q; Wu K
Mol Cancer; 2022 Sep; 21(1):184. PubMed ID: 36163047
[TBL] [Abstract][Full Text] [Related]
9. Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation.
Santiago-Sánchez GS; Hodge JW; Fabian KP
Front Immunol; 2022; 13():993624. PubMed ID: 36159809
[TBL] [Abstract][Full Text] [Related]
10. Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.
Fujimura T; Aiba S
Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32707850
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.
Krishnamoorthy M; Gerhardt L; Maleki Vareki S
Cells; 2021 May; 10(5):. PubMed ID: 34065010
[TBL] [Abstract][Full Text] [Related]
13. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.
Soong RS; Anchoori RK; Yang B; Yang A; Tseng SH; He L; Tsai YC; Roden RB; Hung CF
Oncotarget; 2016 Oct; 7(42):68489-68502. PubMed ID: 27655678
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
[TBL] [Abstract][Full Text] [Related]
15. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
Front Immunol; 2018; 9():398. PubMed ID: 29552012
[TBL] [Abstract][Full Text] [Related]
16. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
17. Myeloid suppressor cells in cancer and autoimmunity.
Sica A; Massarotti M
J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794
[TBL] [Abstract][Full Text] [Related]
18. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
[TBL] [Abstract][Full Text] [Related]
19. The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy.
Li D; Cao D; Sun Y; Cui Y; Zhang Y; Jiang J; Cao X
Front Immunol; 2024; 15():1331641. PubMed ID: 38348027
[TBL] [Abstract][Full Text] [Related]
20. Reverting Immune Suppression to Enhance Cancer Immunotherapy.
Guerrouahen BS; Maccalli C; Cugno C; Rutella S; Akporiaye ET
Front Oncol; 2019; 9():1554. PubMed ID: 32039024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
